ArticleAnaerobe2017
Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin.
Article in Anaerobe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 118 citations in OpenAlex.
- 3D cell assemblies for controlled evaluation of response to dual agent delivery nanofibers targeting bacterial vaginosis.Biomaterials advances · 2026Article
- Vaginal formulations selectively target Lactobacillus iners and Candida spp. while preserving Lactobacillus crispatus.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- The role of probiotics in restoring and maintaining vaginal microbiome health: a review.Infection and immunity · 2026Review
- Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides.Pharmaceutics · 2026Article
- Formulation, development and characterization of fosfomycin tromethamine pessaries for the treatment of vaginal infections.Scientific reports · 2025Article
- From Gut to Reproductive Health: Exploring Microbiome Interactions and Future Interventions.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Postpartum Endometritis and Sepsis Associated withReports (MDPI) · 2025Article
- Antimicrobial and Anticancer Activities ofNutrients · 2025Article
- Article
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- Bacterial vaginosis.Nature reviews. Disease primers · 2025Review
- Metronidazole response profiles of Gardnerella species are congruent with phylogenetic and comparative genomic analyses.Genome medicine · 2025Article
- An in silico framework for the rational design of vaginal probiotic therapy.PLoS computational biology · 2025Article
- Impact of bacterial vaginosis on sexually transmitted viral infections: a bacterial point of view.FEMS microbiology reviews · 2025Review
- Evaluation of Metronidazole Resistance of Vaginal Swab Isolates from South African Women Treated for Bacterial Vaginosis.Antibiotics (Basel, Switzerland) · 2024Article
- Sustained dual delivery of metronidazole and viable Lactobacillus crispatus from 3D-printed silicone shells.Biomaterials advances · 2024Article
- New Aspects in the Study of Lactobacillus iners.Bulletin of experimental biology and medicine · 2024Article
- The Role ofPathogens (Basel, Switzerland) · 2024Review
- Fannyhessea vaginae causing bacteraemia and vertebral osteomyelitis: first report of invasive disease in a male.Access microbiology · 2024Article
- Ecology meets reproductive medicine in HIV prevention: the case for geography-informed approaches for bacterial vaginosis in Africa.Frontiers in reproductive health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Secnidazole, a 5-nitroimidazole with a longer half-life, is structurally related to metronidazole and tinidazole. For treatment of bacterial vaginosis (BV), secnidazole is a suitable single-dose oral drug having a longer serum half-life than metronidazole. The objective of this study was to evaluate the antimicrobial susceptibility of vaginal isolates of facultative and anaerobic bacteria to secnidazole, metronidazole, tinidazole and clindamycin. A total of 605 unique BV-related bacteria and 108 isolates of lactobacilli recovered from the human vagina of US women during the years 2009-2015 were tested for antimicrobial susceptibility by the agar dilution CLSI reference method to determine the minimal inhibitory concentration (MIC). The MIC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.